Summary Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoprocta. Nineteen patients with advanced solid tumours were entered into a phase I study to intravenous normal saline flush and they did not develop these complications. Significant decreases of the platelet count and total leucocyte, neutrophil and lymphocyte counts were seen in the first 24 h after treatment at the dose of 65 jig m2. Immediate decreases in haemoglobin of up to 1.9g dl-' were also noted in patients treated with 65 iLg m2, in the absence of clinical evidence of bleeding or haemodynamic compromise. No effect was observed on the incidence of haemopoietic progenitor cells in the marrow. Some patients' neutrophils demonstrated enhanced superoxide radical formation in response to in vitro stimulation with opsonised zymosan (a bacterial polysaccharide) but in the absence of this additional stimulus, no bryostatin 1 effect was observed. Lymphocyte natural killing activity was decreased 2 h after treatment with bryostatin 1, but the effect was not consistently seen 24 h or 7 days later. With the dose schedule examined no antitumour effects were observed. We recommend that bryostatin 1 is used at a dose of 35 to 50 jg m-2 two weekly in phase II studies in patients with malignancies including lymphoma, leukaemia, melanoma or hypernephroma, for which pre-clinical investigations suggest antitumour activity.
Bryostatin 1 is a natural product isolated from the marine invertebrate Bugula neritina, a member of the phylum Ectoprocta (Pettit et al., 1982) . The drug has a complex macrocyclic lactone stucture with a molecular weight of 904 daltons (see Figure 1 ) and is the prototype of a novel family of potent activators of protein kinase C (PKC: Berkow & Kraft, 1985; Fields et al., 1988) . Bryostatin 1, in common with phorbol esters which are also potent activators of PKC (Castagna et al., 1982) , elicits a wide range of biological responses including induction of differentiation, haemopoietic stimulation, platelet aggregation and immunoenhancing activity. However in a number of systems bryostatin 1 behaves differently from the phorbol esters. Unlike phorbol esters, bryostatin 1 does not induce differentiation of human bronchial epithelium (Jetten et al., 1989) or primary mouse epidermal cells (Sako et al., 1987) and pre-treatment with bryostatin 1 can serve to inhibit the phorbol ester response.
In addition, bryostatin 1 can cause protein phosphorylation at doses that require a far greater molar concentration of phorbol ester to achieve the effect (Fields et al., 1988; Warren et al., 1988) . Furthermore, unlike phorbol ester, bryostatin 1 is inactive as a complete tumour promoter or carcinogen and acts to inhibit the tumour promoting properties of phorbol esters (Hennings et al., 1987) .
Bryostatin I has been shown to have significant in vitro antineoplastic effects against murine and human leukaemia cell lines, the L1OA B-cell lymphoma, the M5076 reticulum cell sarcoma, ovarian carcinoma, the melanoma cell lines SK-MEL5 and B16, the renal cell line A549 and the lung carcinoma cell line A704 (NCI Antitumour Screening Program; Pettit et al., 1982; Dale & Gescher, 1989; Kraft et al., 1989; Hornung et al., 1992 antitumour activity has been observed in in vivo murine models for leukaemia, ovarian carcinoma, B-cell lymphoma, reticulum cell sarcoma and melanoma (Pettit et al., 1982;  Schuchter et al., 1991; Hornung et al., 1992) . Recently it has been demonstrated in mice that there is a close correlation between the in vitro and in vivo antitumour effect of bryostatin 1, suggesting a direct mechanism of action for the drug in vivo (Hornung et al., 1992) .
Numerous studies have demonstrated the potent differentiating effect of bryostatin 1, particularly on fresh human acute and chronic myelogenous and lymphocytic leukaemias (Kraft et al., 1989; Lilly et al., 1990; Lilly et al., 1991) . However, bryostatin 1 has shown varying ability to differentiate immortal HL 60 chronic myelomonocytic leukaemia cell lines, ranging from some differentiation to little or no effect (Kiss et al., 1987a; Kiss et al., 1987b; Kraft et al., 1989; Stone et al., 1988; William et al., 1988; Warren et al., 1988) . The terminal differentiating effect of bryostatin 1 would appear to produce cytostasis in immortal human cell lines but is largely cytotoxic in a variety of fresh human myeloid leukaemia cells (Lilly et al., 1990; Lilly et al., 1991) . Here it has been suggested that the differential effect of bryostatin 1 on fresh and immortal leukaemia cells may exist because of differential expression of PKC isoenzymes (Lilly et al., 1991 (Jalava et al., 1990) .
As 
Patients
Nineteen patients were entered into this study. All had advanced solid tumours for which conventional therapy was not available or had failed (see Table I ). Inclusion criteria were a Karnofsky performance status of >,70, age greater than 18 years, life expectancy of at least three months and a negative stool guaic. The patients had to have normal coagulation (prothrombin time and partial thromboplastin Polymorph phagocytic function Phagocyte function was measured essentially as described by Easmon et al. (1980) by the technique of luminol-dependent chemiluminescence using zymosan as the stimulating agent. The test was performed using disposable polystyrene cuvettes (Clinicon) containing 700 jtl luminol (Sigma 10-4 M in RPMI-H), 200 LI of freshly opsonised zymosan (Zymosan A, Sigma) and 100 yil cell suspension (containing 5 x 106 polymorphs ml-'). Cuvettes were counted repeatedly at 3 min intervals for 30 min using a LKB 1251 Luminometer and the results expressed as mean values for the peak chemiluminescence (in mV). All samples were set up in duplicate.
Results
Nineteen patients were entered into this study, three at each of the dose levels 5, 10 and 20 ,.g m-2, two at 35 1tg m-2, five at 50 ttg m2 and three at 65 gLgm2 (see Table I ). Twelve patients had received prior intensive chemotherapy. Six patients with mesothelioma and one patient with colon cancer had received no prior chemotherapy or radiotherapy.
Toxicity
The severity and duration of clinical toxicity was dose related. Several patients developed increasing severity of symptoms with repeated injections of bryostatin 1. Flu-like symptoms of maximum WHO grade 2, (ie moderate severity), such as lethargy, fever, sweats, rigors, rhinitis and headache accounted for most of the clinical toxicity (see Table II ). Hypotension, of maximum WHO grade 1, occurred in six patients. The dose limiting toxicity was myalgia, often associated with mild to moderate muscle tenderness. Several patients complained of retro-orbital pain on moving their eyes, and upper dysphagia, both of which we attributed to myalgia in these areas. One patient developed WHO grade 2 myalgia at the starting dose level of 5 pg m-2. Other patients treated at 5 lg m2 and patients treated at 10 and 20 sg m-2 did not develop this side effect. Both patients treated at the dose level of 35 tg m-2 and three of the patients at 50 yg m-2 developed myalgia which was of maximum WHO grade 2. All three patients treated at 65 jig m-2 developed WHO grade 3 myalgia which necessitated confinement to bed for one or more days, or which required significant amounts of analgesia to relieve the discomfort. One of these three patients developed WHO grade 3 myalgia following the first cycle of treatment and the other two patients following the second and third cycles of treatment respectively. They were not given subsequent cycles of treatment. Several patients complained of myalgia getting worse with successive cycles of treatment but this was not true of all patients. The pathogenesis of the myalgia is unknown. Creatinine phosphokinase levels remained within the normal range in the three patients who developed WHO grade 3 myalgia. Electromyography was performed also in all three patients and was normal in two. The third patient's electromyographic trace was slightly abnormal and showed several areas of muscle where there were short polyphasic units and which could be compatable with some patchy myositis.
Cellulitis and thrombophlebitis at the bryostatin 1 infusion site complicated 19 of the total 36 cycles of treatment given to the patients treated up to 35 jg m-2 and two of the patients treated at 50 lg m-2. These complications occurred at all dose levels but slightly more regularly at the higher dose levels. We believe that the ethanol diluent was the major cause of the phlebitis and cellulitis when it occurred but we cannot exclude bryostatin 1 itself as a contributory factor. Subsequent patients treated at 50 and 65 ,tg m-2 received an intravenous normal saline infusion with their bryostatin 1 treatment in order to flush the bryostatin 1 solute and ethanol diluent from the treatment vein. There was only one case of mild phlebitis out of a total 13 cycles of treatment given in this way.
There were no apparent effects on coagulation, serum biochemistry or liver function assessed regularly following treatment with bryostatin 1.
Effects of bryostatin I on blood count There were no significant changes in any of the haematologic parameters during the administration of bryostatin 1 at doses of 5, 10, 20, 35 and 50 igm2 day-'. The three patients treated at the dose of 65 .tg m-2 showed decreases of 34-44% in platelet counts with the nadir occurring in the first 4 h. Recovery of the platelet count was usually taking place at 24h following treatment and full recovery was usually evident at one week (Figure 2) .
A reduction in the neutrophil count also occurred in the first 24 h following administration with decreases of 44-64% at 65 jtg m-2 (Figure 3) . Reductions in the lymphocyte count also occurred with decreases of 55-88% at 65 ytg m-2 (Figure 3 ). Of particular interest were immediate decreases in haemoglobin values observed in the first 4 h after treatment with bryostatin 1, most notable in patients treated at the dose of 65 Lg m-2 with decreases of up to 1.9 gdl-' (see Figure 4) . Unlike decreases in platelet, neutrophil and lymphocyte counts, recovery of the haemoglobin values was not noted in the next 2 weeks. There was no clinical evidence of bleeding and the patients showed no evidence of haemodynamic compromise.
Bone marrow clonogenic assays In vitro clonogenic assays of haemopoietic progenitors were performed on bone marrow aspirates taken before the first bryostatin 1 infusion and 24 h after the final treatment from In patients 14 to 18, a decrease in the NK activity (against K562) was observed 2 h following treatment (see Table IV ). In all cases, subsequent levels of NK were low but gradually increased over the 7 day observation period. Endogenous LAK activity (against Daudi cells) followed a similar trend. No dose-dependent differences were observed in NK activity. to treatment with bryostatin 1. Myalgia, aggravated by exercise, emerged as the dose limiting toxicity usually occurring about 48 h after threatment and lasting up to several weeks at the highest dose levels. Several patients complained of increasing myalgia with successive cycles of treatment. The pathogenesis of this toxicity is uncertain and there was no clear evidence compatible with either myositis or myolysis. Muscle tenderness was evident in many patients but was not a prominent feature. Electromyography (EMG) demonstrated some evidence of patchy myositis in one of three patients treated at 65 Ltg m-2. Serum creatinine phosphokinase (CPK) levels remained within the normal range in the same three patients. In vitro work has shown that bryostatin 1, like other protein kinase C activators, induces electrical membrane instability in genetically normal muscle, leading to an unscheduled series of action potentials (Brinkmeier & Jockusch, 1987) . These findings were caused by a drastically lowered sarcolemma chloride conductance. If this was the cause of the myalgia in our patients, one would have expected florid changes on the EMG's which did not occur. Another possible explanation for the myalgia is ischaemia cause by platelet microemboli (i.e. platelet aggregates) but there was no rise in CPK levels secondary to ischaemia-induced necrosis.
Cellulitis and thrombophlebitis at the bryostatin 1 infusion site complicated 53% of cycles of treatment administered without an accompanying normal saline venous flush. We believe that these complications resulted from the 60% ethanol diluent in the bryostatin 1 infusion, though we cannot exclude the possibility that the bryostatin 1 itself may have been a contributing factor.
Bryostatin 7 has been shown to be a potent inducer of human platelet aggregation in vitro (Tallant et al., 1987) and we have demonstrated similar activity by bryostatin 1 in vitro and in vivo (data not shown). Mouse and rat toxicity studies have also shown a profound in vivo effect of bryostatin 1 on platelets. In this phase 1 study we observed a drop in platelet counts only at the bryostatin 1 dose of 65 jig m-2, occurring usually up to 4 h after treatment. Platelet aggregation was not profound and decreases of only 34-44% in the platelet count were observed. Pre-clinical toxicity studies demonstrated more profound platelet count drops and occasionally with significant internal bleeding, but at relatively higher bryostatin 1 doses than we used in this phase 1 trial. The emergence of dose limiting myalgia has meant that we did not approach bryostatin 1 doses in this trial where we might encounter profound platelet aggregation and run a significant risk of bleeding.
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Decreases in the haemoglobin values of up to 1.9 gdl-in patients treated at the bryostatin 1 dose of 65 lg m-2 are unexplained. There was no clinical evidence of bleeding or haemodynamic compromise. Haemolysis may explain the finding.
Transient reductions in the neutrophil and lymphocyte counts also occurred at the dose of 65 jLg m-2 in the first 24 h after treatment. These may have been due to the sequestration of functionally active leucocytes. No evidence of toxicity on haemopoietic progenitor cells was found in clonogenic studies on bone marrow taken from these patients. Preclinical toxicity studies have demonstrated significant reductions in lymphocyte counts lasting up to 29 days after treatment with bryostatin 1, but at relatively higher doses than we achieved in this phase 1 trial. Bryostatin 1 functionally activates intact human polymorphonuclear leucocytes, enhancing cytotoxicity and release of superoxide radicals and specific granules (May et al., 1987; Berkow & Kraft, 1985) . We were unable in this phase I trial to clearly demonstrate enhanced production of superoxide radicals by neutrophils taken from patients treated with bryostatin 1 at doses of 20, 35, 50 and 65 jlg m-2. However, if these neutrophils were additionally stimulated in vitro, using opsonised zymosan an enhanced production of superoxide radicals were seen in seven patients at doses of 20, 35, 50 and 65 jig m-2. The doses of bryostatin 1 administered in this phase 1 trial were not on their own, enough to stimulate directly the release of superoxide radicals but were sufficient to 'prime' the neutrophils for an enhanced response to a second stimulus.
Bryostatin 1 exerts pleiotropic effects on human lymphocytes in vitro including the activation and induction of proliferation of both T and B cells (Trenn et al., 1988; Hess et al., 1988; Drexler et al., 1990 ) and the induction of interleukin-2 receptors (IL-2R) on T cells (Hess et al., 1988) . Conflicting evidence exists on the ability of bryostatin 1 to enhance or trigger human lymphocyte mediated cytotoxicity. Trenn et al., 1988 , have reported on the ability of bryostatin 1 to trigger cytotoxic T lymphocyte (CTL) development in naive resting lymph node cells and to trigger cytotoxicity of CTL clones against antigen (Ag) -non bearing target cells. However, CTL cytotoxicity against Ag-specific target cells was inhibited. Bryostatin 1 was also shown to greatly enhance the efficiency of recombinant interleukin-2 (rIL-2) in triggering development of in vivo primed CTL during in vitro incubation. In all patients monitored in our study the NK activity decreased initially following administration of bryostatin 1. However, since the actual values obtained for % cytotoxicity were low the significance of these differences has to be interpreted with caution. Similar observations were made in vitro by Tilden and Kraft (1991) who found a suppression of NK activity following an 18 h preincubation of lymphocytes with 10-8 M bryostatin 1. These authors also observed reduced cytotoxic activity of LAK effector cells following coincubation with rIL-2 and 10-8 M bryostatin 1. It will be of interest to study the in vitro LAK activities of lymphocyte populations of patients receiving bryostatin 1.
Bryostatin 1 exerts a wide variety of stimulatory effects on bone marrow progenitor cells and peripheral blood cells. Originally bryostatin 1 was reported to enhance proliferation of human and murine haemopoietic progenitor cells, including committed myeloid progenitor cells (CFU-GM) and early and late erythroid progenitors (BFU-E and CFU-E: May et al., 1987; Leonard et al., 1988; Gebbia et al., 1988) . Subsequently it has been shown that this is an indirect effect and includes the augmentation of the response by haemopoietic progenitors to the haemopoietic growth factors, granulocyte macrophage colony stimulation factor (GM-CSF) and interleukin-3 (IL-3: McCrady et al., 1991; Sharkis et al., 1990) and perhaps also the stimulation of accessory cell populations, including T cells, to produce GM-CSF and IL-3 (Sharkis et al., 1990; Leonard et al., 1988) . We were unable in this phase 1 trial to demonstrate changes in the incidence of progenitor cells in the marrow.
Pre-clinical studies have demonstrated that bryostatin 1 is an extremely potent antineoplastic agent. The marine animal origin, macrocylcic lactone structure and PKC receptor mechanism make it one of the most unusual anti-tumour agents to become available for phase I clinical testing. In addition, only extremely low doses are required to produce a biological effect in vivo. We recommend phase II clinical testing at a bryostatin 1 dose of 35 to 50 jig m-2 two weekly in patients with malignancies including lymphoma, leukaemia, melanoma or hypernephroma for which preclinical studies suggest antitumour activity. We are currently evaluating weekly treatments by 24 h infusion at a bryostatin 1 dose of 25 to 50 tLg m in patients with malignancies including lymphoma.
